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'Elevated hepatocyte paraffin 1 and neprilysin expression in hepatocellular carcinoma 
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Le carcinome hépatocellulaire reste une tumeur maligne de mauvais pronostic. Le but de 
cette étude rétrospective est d'étudier l'expression immunohistochimique semi-quantitative 
d'Hep Par 1 (hepatocyte paraffin 1) et de CDlO (CALLA ou neprilysin) et leur valeur 
pronostique sur un collectif de 97 patients avec un carcinome hépatocellulaire traité à visée 
curative. 
Hep Par 1 réagit avec un épitope spécifique de l'hépatocyte au niveau de la membrane 
mitochondriale et se présente sous forme d'un marquage cytoplasmique diffus d'intensité 
variable, le foie non tumoral exprimant un marquage granulaire servant de contrôle interne 
positif. Le CD 10 correspond à une metallopeptidase de la membrane cellulaire participant au 
processus de sécrétion hormonale et l'immunoréaction colore spécifiquement la portion 
luminale des canalicules biliaires du foie non tumoral, qui sert ainsi de contrôle interne 
positif. Le foie tumoral exprime ou non un marquage canaliculaire (CD 10 can), similaire au 
foie non tumoral, ou cytoplasmique (CDlO cyt). 
Le marquage immunohistochimique est quantifié pour les 3 différents marqueurs (Hep Par 1, 
CDlO can et CDlO cyt) en fonction du pourcentage de cellules tumorales positives (score de 
0 à 3 établi pour chaque marqueur immunohistochimique). L'élaboration d'un score combiné 
immunohistochimique (CIS) est obtenu en additionnant les scores d'Hep Par 1 et de CDl 0 
can et en soustrayant le score de CD 10 cyt. 
Dans l'analyse univariée, la survie globale des patients est prolongée de manière significative 
en cas de forte expression tumorale par Hep Parl (p=0,0005) et CDlO can (p=0,02). Dans 
l'analyse multivariée, la combinaison du CIS avec les autres paramètres histopathologiques 
pronostiques classiques du carcinome hépatocellulaire comme la taille tumorale, l'invasion 
vasculaire, la multifocalité de la tumeur et le grade tumoral montre que le score 
immunohistochimique combiné (CIS) reste le facteur pronostique le plus important 
(p=0,001). Les patients avec un CIS bas (<4) avec une survie moyenne de 17 mois ont 3,5 
fois plus de risque de décès comparés à ceux avec un CIS élevé (>4) avec une survie 
moyenne de plus de 80 mois. 
En conclusion, une expression immunohistochimique élevée d'Hep Par 1 et de CDlO can en 
l'absence d'expression de CD 10 cyt sont des facteurs pronostiques favorables pour les 
patients présentant un carcinome hépatocellulaire. La combinaison des marqueurs 
immunohistochimiques dans un score combiné pourrait être utilisé dans la prise en charge 
des patients avec un hépatocarcinome à visée curative. Toutefois des études prospectives 
restent nécessaires pour confirmer l'utilité pronostique du CIS. 
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Abstract Hepatocyte paraffin 1 (Hep Par 1) and neprilysin 
(CDlO) are well-known markers of hepatocellular carci-
noma (HCC). To assess their potential prognostic role, we 
conducted a retrospective analysis of97 formalin-fixed and 
paraffin-embedded HCC from patients treated by surgery 
with curative intent, using standard immunohistochemical 
procedures and semiquantitative analysis. Strong Hep Par 1 
expression and canalicular CD 10 staining pattern were 
significantly correlated with smaller tumor size (p=0.007 
and 0.04, respectively). On univariate analysis, longer 
overall survival was observed in patients with strong Hep 
Par 1 expression (p=0.0005) and in patients with a 
CDlOcan staining pattern (p=0.02). On multivariate anal-
ysis, the combined immunohistochemical score (CIS) 
obtained by addition of Hep Par 1 and CD 1 Ocan scores 
and subtraction of cytoplasmic CD 10 score was retained as 
the single most important prognostic factor (p=0.001 ). 
Patients with a CIS <4 had a 3.5-fold increased risk of 
death, as compared to those with a CIS 2:4. In conclusion, 
strong Hep Par 1 expression, presence of CD 1 Ocan 
labeling, and absence of CDlOcyt staining are favorable 
prognostic factors in HCC, which can be easily combined 
into a single immunohistochemical score for routine 
clinical use. 
Keywords Carcinoma · Hepatocellular · 
Immunohistochemistry · Antibodies · Monoclonal · 
Prognosis 
D. Mondada · F. T. Bosman · C. Fontolliet · 
W. K. F. Seelentag ([81) 
Institute of Pathology, University of Lausanne, 
Bugnon 25, 
1011 Lausanne, Switzerland 
e-mail: Walter.Seelentag@hospvd.ch 
Tel.: +41-21-3147208 
Fax: +41-21-3147115 
Introduction 
Prognosis ofhepatocellular carcinoma (HCC) after hepatic 
resection with curative intent remains very poor despite 
improved surgical techniques [ 17, 23, 26]. In addition, in 
low endemic areas like Switzerland, HCC is often dis-
covered in elderly patients with a long-standing alcoholic 
cirrhosis and at high operative risk. Therefore, adequate 
prognostic stratification of the patients to guide the clini-
cian in treatment choice is essential. The most important 
histopathologic prognostic factors are tumor size, vascular 
invasion, tumor multifocality, and tumor grade [1, 24, 29, 
30]. Combined scores based on histological features or 
image analysis have also been proposed [23]. In addition, 
the prognostic significance of a variety of gene products 
related to the cell cycle or to cell adhesion has been de-
scribed in the literature, such as the tumor-suppressor gene 
p53, the cell cycle inhibitors p21, p27, and cyclin D, and 
the cell adhesion molecule beta-catenin [ 18, 20, 31 ]. How-
ever, none of these markers have found their way into 
routine clinical use. 
Hepatocyte paraffin 1 (Hep Par 1) [2, 21, 27, 38] and 
neprilysin (CDlO or CALLA) [5, 40] are well-established 
markers of HCC, and their use as diagnostic aid is well 
documented in the literature. Hep Par 1 bas been obtained 
by immunizing mice with a crude antigen extracted from 
human liver tissue [38]. It reacts with a hepatocyte-specific 
epitope of the mitochondrial membrane [21, 22, 38], re-
sulting in a granular cytoplasmic staining pattern. This 
marker bas been shown to be highly specific for normal and 
neoplastic liver tissue. CD 10 is a zinc-dependant cell mem-
brane metallopeptidase, which participates in the postsecre-
tory processing of neuropeptidases and peptide hormones 
[3 7]. In the past, it has been widely used as a marker of 
lymphoblasts in acute lymphoblastic leukemia [ 4]. More 
recently, it has also been shown that CD 10 is expressed on 
the canalicular domain of the cell membrane in normal and 
neoplastic liver tissue [7, 11, 12]. 
Specificity of these two markers bas been well estab-
lished in the literature, allowing the distinction of HCC 
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from cholangiocarcinomas and carcinoma metastases to the 
liver [25, 27, 28]. Surprisingly, to our knowledge, despite 
several studies on the diagnostic value ofthese markers and 
their association with tumor grade and growth pattern, the 
possible association of their expression with survival has 
never been examined in detail. In reviewing our pilot series 
of HCC, the extent of Hep Par 1 and canalicular CD 10 
(CD lOcan) expression seemed to be related to the degree of 
differentiation. In contrast, cytoplasmic CD 10 (CD lOcyt) 
expression seemed to be restricted to cases with low Hep 
Par 1 and CD 1 Ocan expression. We therefore decided to 
systematically evaluate the prognostic value ofthese three 
parameters. In the current retrospective study, we analyze 
the immunohistochemical expression of Hep Par 1 and 
CDlO in foimalin-fixed and paraffin-embedded HCC 
tissue from patients who underwent either partial hepatec-
tomy with curative intent or total hepatectomy followed by 
liver transplantation to assess their prognostic value. 
Patients and methods 
Patients and tissue samples 
All patients (n=122) who underwent either partial hepa-
tectomy with curative intent or total hepatectomy with liver 
transplantation because of primary HCC and who were 
diagnosed at the Institute of Pathology in Lausanne, Swit-
zerland, between January 1992 and May 2001 were se-
lected for this retrospective study. Excluded were patients 
with mixed hepato-choloangiocarcinoma (n=8), fibrolamel-
lar carcinoma (n=l), inadequate follow-up (n=ll), missing 
material for immunohistochemistry (n=2), and patients who 
<lied within 30 days after diagnosis (n=3). The ethics com-
mittee of our institution approved the study protocol. 
The remaining 97 patients consisted of typical Western 
European patients whose clinical characteristics were sim-
ilar to those of several other published series [9, 26, 32]. 
Treatment was partial liver resection in 72 patients (74%) 
and total hepatectomy followed by liver transplantation in 
25 patients (26%). Most patients (78%) were men. The 
median age was 63 years (range 14 to 89 years) and was 
similar for male and female patients. Cirrhosis was found in 
67 patients (69%). Serology was positive for hepatitis B 
virus surface antigen in 10 patients (10%) and hepatitis C 
virus antigen in 18 patients (19% ). Preoperative aspartate 
aminotransferase, alanine aminotransferase, gamma gluta-
myl transferase, and alpha-fetoprotein (AFP) levels were 
also recorded. Overall survival time was calculated from 
date of diagnosis to date of death or date of last follow-up 
until closure of the study which was chosen at 30 August 
2002. Inte1mediate outcomes were not considered. Median 
follow-up time computed according the Kaplan-Meier 
estimate of potential follow-up was 47 months. Overall 
median survival time was 28 months in the whole cohort 
and 23 months in the subgroup of patients treated with 
partial hepatectomy. 
All specimens were fixed in 10% buffered formalin and 
embedded in paraffin according to standard histological 
practice. All available hematoxylin/eosin-stained sections 
(mean 3, range 1 to 12) were reviewed by two experienced 
pathologists (D.M. and C.F.), and a representative paraffin 
block containing both carcinoma and nontumorous tissue 
was selected for immunohistochemistry. Tumor stage was 
determined using the International Union against Cancer's 
tumor-nodes-metastasis (TNM) classification of malig-
nant tumors [34]. Because of small sample size, stages p Tl 
and pT2 were grouped together. Tumors were divided into 
grades 1, 2, 3, and 4 according to Edmondson and Steiner 
[13]. In the case of a heterogeneous tumor, the highest 
grade was retained for the database. Classification of tumor 
architecture into trabecular, acinar, compact, and scirrhous 
growth pattern was performed according to the World 
Health Organization's criteria [ 16]. Because of relatively 
low numbers of tumors in the various non-trabecular cat-
egories, they were grouped together for statistical analysis. 
Tumor size, tumor multifocality (solitary nodules/multiple 
nodules), and microvascular invasion (MVI) were also 
recorded. Hepatocellular Prognostic Index (HPI) was com-
puted according to Lauwers et al. [23], using the following 
formula: HPI = (MVI status x 0.459) + (nuclear grade x 
0.287). Two prognostic groups were derived from this index: 
HPI-low (HPI:S0.746), corresponding to patients with 
rather good prognosis according to Lauwers et al. [23], 
and HPI-high (HPI>0.746), corresponding to patients with 
poor prognosis. 
With regard to tumor stage, 33 patients (34%) had stages 
I and II disease, 29 (30%) had stage III, and 35 had (36%) 
stage IV. Most HCC were less than 5 cm in size (11=58, 
60%), solitary (n=54, 56%), and with a trabecular archi-
tecture (n=75, 77%). The tumor differentiation was grade 1 
in 15 HCC (15%), grade 2 in 47 (48%), grade 3 in 27 
(28%), and grade 4 in 8 (8%). MVI was present in 35 HCC 
(36%). HPI was high in 51 tumors (53%). 
Immunohistochemistry 
Immunohistochemistry was performed with mouse mono-
clonal antibodies directed against Hep Par 1 (clone OCHIE5, 
DAKO) and CDlO (clone 56C6, Novocastra) using the 
streptavidin biotin complex (ABC) method. In brief, 3--4 µ 
tissue sections were mounted on aminopropylmethoxysi-
lane-coated slides, deparaffinized in xylene, and rehydrated 
in a graded alcohol series. Endogenous peroxidase was 
blocked with 1 % H20 2 in methanol for 30 min at room 
temperature. Antigen retrieval was performed by boiling 
the sections (microwave) in 10 mM citrate buffer pH 6.0 
for 15 min (Hep Par l) or 1 mM in EDTA pH 7 .5 for 15 min 
(CDlO). After conditioning with normal horse serum at a 
1 :30 dilution for 5 min, the sections were incubated either 
with anti-Hep Par 1 at a 1: 10 dilution for 1 h or with anti-
CD 10 at a 1 :20 dilution overnight. Detection was per-
formed using biotinylated anti-mouse IgG at a 1 :200 
dilution and peroxidase-conjugated ABC complex (both 
from Vector Laboratories) according to the manufacturer's 
specifications. Between all steps, sections were washed in 
Tris-buffered saline. Peroxidase activity was revealed with 
3,3-diaminobenzidine-tetrahydrochloride as chromogen, and 
sections were counterstained with Mayer's hematoxylin. 
Primary antibodies were omitted as a negative control. 
Nontumorous liver tissue adjacent to HCC and present on 
the same slide was used as positive control. 
The immunohistochemical Hep Par 1 and CD 10 staining 
of all slides was evaluated independently by two observers 
(D.M. and W.K.F.S) in a blinded manner. Divergent scor-
ings were discussed until a consensus was reached. To 
assess reproducibility, a subset of slides was analyzed by a 
third pathologist (F.T.B.), who had not done the initial 
evaluation based on the information contained in this 
manuscript without additional training. Individual tumor 
cells were considered to be positive for Hep Par 1 when 
their cytoplasmic staining intensity was similar or stronger 
than that of the adjacent nontumorous hepatocytes. CDlOcyt 
staining was considered to be positive in tumor cells when 
the cytoplasm showed unambigous labeling in contrast to 
the preexisting hepatocytes which were negative. Positive 
CD 1 Ocan staining was defined as crisp focal labeling of the 
canalicular aspects of the tumor cell membrane when its 
intensity was similar or stronger than that of the non-
tumorous canaliculi. 
Based on the percentage of positive cells, Hep Par 1, 
CDlOcan, and CDlOcyt immunolabelings were semiquan-
titatively classified into four groups, based on a priori 
determined cutoffpoints. In the first group, less than 5% of 
the tumor cells were positive (score O); in the second group, 
5 to 30% of the tumor was positive (score 1 ); in the third 
group, 30 to 90% of the tumor cells were positive (score 2); 
and in the last group, more than 90% of the tumor was 
positive (score 3). 
A combined immunohistochemical score (CIS) was 
computed as follows: CIS =Hep Par 1 score+ CDlOcan 
score - CD 1 Ocyt score. 
Statistical analysis 
C01Telation tests between immunohistochemical and clin-
icopathological parameters were performed using either 
Kruskal-Wallis tests (for continuous or ordered variables 
such as age, HPI, or tumor grade) or Chi-squared tests (for 
categorical variables), unless there was concem regarding 
an inadequate number of observations, in which case, a 
Fisher's exact test was used [3]. 
Overall interobserver agreement was compared using 
kappa statistics. According to common usage, kappa values 
of :S0.5 were considered "poor", 0.51-0.6 "moderate", 
0.61-0.8 "good", and >0.8 "excellent". 
For Fisher's exact tests and survival analysis, clinico-
pathological and immunohistochemical variables were di-
chotomized into groups of similar size as follows: age <65 vs. 
2:65 years, tumor size ::;5 vs. >5 cm, HPI ::;0.746 (low) vs. 
>0.746 (high), Hep Par 1 <3 vs. =3, CDlOcan <2 vs. 2:2, 
CDlOcyt <l vs. 2:1, and CIS <4 vs. 2:4. 
Survival percentages over time were calculated by 
the Kaplan-Meier method [19], and their corresponding 
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standard errors were determined using the formula of 
Greenwood [15]. Univariate associations between the po-
tential prognostic factors and overall survival were tested 
using the log-rank test. 
Prognostic variables which had been at least marginally 
significant in univariate analysis (log-rank test <0.1) were 
further analyzed in various Cox regression models using 
backward selection with p<0.05 as the exit criterion. 
Given the relatively small number of outcome events, 
several distinct Cox regression models with a limited 
number of covariates had to be evaluated [6]. 
Estimated hazard ratios of death, with respect to the 
indicated reference group, their 95% confidence intervals 
(CI), and p values were calculated with appropriate binary 
variables to identify each group of interest [ l O]. Values of 
hazard ratios greater than unity indicated increased rates of 
death with respect to the chosen reference category. 
To evaluate the impact of type of surgery, univariate and 
multivariate analysis were done on the whole study pop-
ulation as well as on the subgroup of patients with partial 
liver resection. 
Statistical analyses were carried out by means of the 
software packages Stata, S-plus 2000, and SPSS. 
All probability values were evaluated by two-sided tests, 
and differences were considered to be significant if the 
p value was less than 0.05. 
Results 
Correlation of Hep Par 1 and CD 10 immunolabeling 
with clinicopathological features 
Hep Par 1 resulted in a diffuse labeling of the cytoplasm of 
nontumorous hepatocytes, which served as intemal posi-
tive control, with a distinctive granular pattern. It was in-
dependent of the underlying li ver pathology, and there was 
no staining difference between cirrhotic and non-cirrhotic 
liver tissue. Most HCC showed a similar cytoplasmic 
labeling, albeit at a highly variable intensity (Fig. la-c). 
Hep Par 1 expression, evaluated semiquantitatively as 
outlined in "Patients and methods", was extensive (score 3) 
in 54 (55%) HCC, partial (score 2) in 31 (32%) HCC, and 
focal or absent (score 1 or 0) in 13 (13%) HCC. 
CDlO labeled in nontumorous liver exclusively the 
luminal portion ofbile canaliculi of the hepatocytes as well 
as the luminal surface of the bile duct epithelium. There 
was no staining difference between cirrhotic and non-
cirrhotic liver. In HCC, a similar canalicular staining pat-
tern was seen forming sharp branching lines which were 
typically located between cells and not within them 
(Fig. 1 d-f). CDlOcan labeling was widespread (score 3) 
in 20 (21 %) HCC, partial (score 2) in 38 (39%) HCC, focal 
(score 1) in 11 (11 %) HCC, and completely absent in 28 
(29%) HCC. In addition, some HCC displayed a CDlOcyt 
labeling (Fig. 1 g,h), and very few tumors exhibited a 
diffuse cell membrane staining. This type of staining was 
not seen in nontumorous hepatocytes. CD lücyt staining 
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Fig. 1 Representative examples 
of irnmunohistochemical stain-
ing in HCC for Hep Par 1 (a-c) 
and CDIO (d-h): individual 
tumor cells (tu) are considered 
positive for Hep Par 1 when 
their cytoplasmic immunolabel-
ing is similar to that of adjacent 
nontumorous hepatocytes (11). 
CDI 0 labeling is considered to 
be canalicular (d-f) when there 
is a crisp linear staining between 
adjacent tumor cells (inset , d). 
CD 1 Ocyt staining is considered 
significant if individual tumor 
cells show an unambigous cy-
toplasmic staining in contras! to 
surrounding nontumorous liver 
tissue which is negative (g-h). 
Scoring is based on the percent-
age of positive tumor cells: 
score 3, more than 90% labeled 
tumor ce lis (a, d, and g); score 
2, between 30 and 90% (b, e, 
and h); and score 1, less than 
30% positive tumor cells (c and 
f). Sca/e bars 100 µm 
was extensive (score 3) in 5 (5%) HCC, partial (score 2) in 
23 (24%) HCC, focal (score 1) in 18 (19%) HCC, and 
absent in 51 (52%) HCC. 
Conelations between immunohistochemical features and 
histopathologic parameters are reported in detail in Table 1. 
High levels of Hep Par 1 expression (score=3) were sig-
nificantly conelated with small tumor size (p=0.007), ab-
sence ofMVI (p=0.03), and low HPI (p=0.04). In addition, 
Hep Par 1 expression decreased with increasing tumor 
grade in a significant manner (p=O.O 1; Fig. 2a). Ali other 
parameters, including International Union Against Cancer 
tumor stage and tumor pattern, lacked any significant cor-
relation with Hep Par 1 score. Extensive CD 1 Ocan labeling 
(score2:2) was more frequent in small HCC (p=0.04) and 
male patients (p=0.01). Like Hep Par 1, CDlOcan expres-
sion was reduced in poorly differentiated tumors (p=0.03; 
Fig. 2b). CDlOcyt staining was not conelated with any 
clinicopathological feature. A . high CIS (2:4) showed a 
highly significant conelation with reduced tumor size 
(p=0.05), and it was also more frequently observed in male 
patients (p=0.04). Fmthe1more, CIS decreased with 
decreasing tumor differentiation (p=0.05; Fig. 2c). 
To assess reproducibility, a subset of immunolabelings 
was reviewed by another pathologist without particular 
training. The interobserver agreement was excellent for 
Hep Par 1 and CDlOcan labeling (K=0.87) and moderate 
for CDIOcyt labeling (K=0.53). 
Conelation of Hep Par 1 and CD 10 expression 
with survival by univariate analysis 
To dete1mine the prognostic value of Hep Par 1 and CD 10 
labeling, the immunohistochemical scores were analyzed 
as categorical variables using cutoff points that were 
chosen in a manner to split the study population in two 
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Table 1 Relationship between expression of Hep Par 1 or CD 10 and pathological factors 
Number of patients with 
Factor Total number Hep Par 1 p valuesa CD 10 canalicular p values CDlO cytoplasmic p values CISb 2:4 p values 
of patients score =3 score 2:2 score 2:1 
Tumor size (cm) 
:S5 58 39 (67%)c 0.007 40 (70%) 0.04 20 (51 %) NS 29 (50%) 0.005 
>5 39 15 (39%) 18 (46%) 26 (45%) 8 (21%) 
MVI 
Absent 62 40 (65%) 0.03 37 (60%) NS 29 (47%) NS 26 (42%) NS 
Present 35 14 (40%) 21 (60%) 17 (49%) Il (31%) 
HPI<l 
Low 46 31 (67%) 0.04 30 (65%) NS 23 (50%) NS 21 (46%) NS 
High 51 23 (45%) 28 (55%) 23 (45%) 16 (31 %) 
NS Statistically not significant 
aTwo-sidedp values obtained by Fisher's exact test, which are considered to be significant ifp<0.05, of marginal significance if0.05:Sp<O.l, 
and not significant if p2'.0.I 
bCIS (score Hep Par 1 staining+score CDlO canalicular staining-score CDlO cytoplasmic staining) 
cPercentages are computed with regard to number of patients for a given factor category 
dHPI according to Lauwers et al. [23] 
groups of similar size. To detect a possible bias resulting 
from the type of surgery, univariate and multiva1iate 
survival analyses were done not only on the whole study 
population but also on the subgroup of patients with partial 
liver resection. On univariate analysis (Table 2) of the 
whole cohort, Hep Par 1 expression and CD 1 Ocan labeling 
were significantly associated with overall survival (p=0.0005 
and 0.02, respectively). Indeed, median survival time of 
patients with tumors showing a strong Hep Par 1 staining 
(score=3) was more than 1 OO months in contrast to patients 
Fig. 2 Correlation between 
Edmondson and Steiner's tumor 
grade and immunohistochemical 
scores: Hep Par 1 expression is 
significantly decreased in grades 
3 and 4 carcinomas (a). 
3 
..... 2 
.. 
:. 
Q. 
Cii 
::c 1 
0 p~ 0.01 
with a score of <3 who survived only 15 months (Fig. 3a). 
Similarly, survival of patients with an at least moderate 
CDlOcan staining (score 2:2) was 54 months in contrast to 
17 months for the other patients (Fig. 3b ). Similar results 
were found in the subgroup of patients with partial liver 
resection, who showed also a significant association of 
strong Hep Par 1 staining with longer median overall 
survival (33 vs. 14 months, p=0.03). There was a trend 
toward better overall survival among patients with a 
CDlOcan score of2':2 (28 vs. 16 months,p=0.09). In contrast, 
D a 3 
0 
2 3 4 
p= 0.03 
..... 
2 3 4 
b 
CD 1 Ocan expression is highly 
decreased in grade 4 tumors (b ). 
Combined immunohistochemi-
cal score (CIS=Hep Par 1 score+ 
CD lücan score - CD 1 Ocyt 
score) shows a progressive de-
crease with increasing tumor 
grade (c). p values were deter-
mined using Kruskal-Wallis 
tests Edmondson grade Edmondson grade 
3 ~ 2 
6 
5 $ 4 c 
0 
-1 p= 0.05 
2 3 4 
Edmondson grade 
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Table 2 Univariate analysis of the immunohistochemical factors 
All patients Only patients treated by partial resection 
Immunohistochemical Number of Median survival 95% CI p values• Number of Median survival 95% cr p values 
score patients ( censored) time (month) (month) patients ( censored) time (month) (mon th) 
Hep Par 1 
<3 43 (9) 15 9-21 0.0005 36 (6) 14 6-22 0.03 
=3 54 (32) >100 36 (18) 33 6-60 
CDlO canalicular staining 
<2 39 (11) 17 7-27 0.02 31 (7) 16 6-26 0.09 
2:2 58 (30) 54 24-84 41 (17) 28 4-52 
CDl 0 cytoplasmic staining 
<1 51 (24) 31 17-45 NS 34 (13) 27 10-44 NS 
2:1 46 (17) 27 11-43 38 (11) 16 0--33 
CI Sb 
<4 60 (16) 17 9-25 0.0004 48 (9) 16 13-19 0.004 
2:4 37 (25) >80 24 (15) >80 
NS Statistically not significant 
•Two-sidedp values obtained by log-rank test, which are considered to be significant ifp<0.05, of marginal significance if0.05'.'0p<O.l, and 
not significant if p2':0 .1 
bers (score Hep Par 1 staining +score CDlO canalicular staining - score CDlO cytoplasmic staining) 
there was only a weak association between CD 1 Ocyt labeling 
and overall survival in the whole cohort (p=0.2) and in the 
subgroup of patients with partial resection (p=0.3). Patients 
with CDIOcyt positive tumors tended to have a reduced 
overall survival as compared to patients with CD 1 Ocyt 
negative tumors. 
Fig. 3 Overall survival curves 
of all 97 patients who underwent 
either partial hepatectomy with 
curative intent or total hepatec-
tomy with liver transplantation 
according to Hep Par 1 score 
(a), CDlOcan score (b), corn-
bined immunohistochemical 
score (CIS=Hep Par 1 score + 
CD 1 Ocan score - CD lücyt 
score) ( c ). Overall survival 
curves of the subgroup of 72 
patients who underwent partial 
hepatectomy with curative intent 
according to combined immu-
nohistochemical score (d). 
p values were determined 
using the log-rank test 
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To be able to use these immunohistochemical parameters 
. · a routine clinical setting, they were combined into a 
:mp1e score according to the following formula: CIS = 
Hep Par 1 score + CDlOcan score - CDlOcyt score. On 
univariate analysis, there was a highly significant correla-
tion between CIS and overall survival in both the whole 
cohort (p=0.0004) and the patients with partial liver 
resection (p=0.01). In the whole study population, patients 
with a CIS 2':4 survived more than 80 months whereas the 
median overall survival of the others was only 17 months 
(Fig. 3c ). Similar median overall survival times were found 
in the subgroup of partially resected patients (80 vs. 
16 months; Fig. 3d). 
Multivariate survival analysis 
Multivariate analysis was perfonned using several Cox 
regression models with a limited number of covariates, 
because the number of outcome events did not allow the 
evaluation of all pertinent parameters at once. Prognostic 
variables which had been at least marginally significant 
(log-rank test <0.1) in uni varia te analysis (tumor size, 
Table 3 Univariate analysis of the clinicopathological factors 
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stage, multifocality, and grade as well as MVI, BPI, and 
surgical margins; Table 3) were further analyzed in various 
Cox regression models using backward selection with 
p<0.05 as the exit criterion. Following clinicopathological 
parameters had no impact on survival in univariate analysis 
and were not further assessed in multivariate models: 
preoperative transaminase levels and cholestatic param-
eters, viral hepatitis B and C, alcohol-related liver disease, 
cigarette smoking, sex, age, and tumor growth pattern. 
Although not statistically significant on univariate analysis 
in our series, concomitant liver cirrhosis and preoperative 
AFP levels were included in a multivariate model because 
they are well-known prognostic markers. 
In the models including only clinicopathological param-
eters, the retained prognostic factors were tumor multifo-
cality and size in the whole cohort and tumor multifocality 
and grade in the subgroup of patients with li ver resection 
(model 1 from Table 4). 
In the mode! including Hep Par 1, CD 1 Ocan, and 
CD 1 Ocyt, all three immunohistochemical parameters were 
retained, and the regression coefficients (whole cohort) 
were 0.72, 0.77, and 0.78 for Hep Par 1, CDlOcan, and 
CD!Ocyt, respectively (model 2 from Table 4). Taken 
_A_ll__,p_a_ti_e1_1t_s _________________ Only patients treated by partial resection 
Factora Number of Median survival 95% CI p valuesb Number of Median survival 95% CI p values 
patients (censored) time (month) (month) patients (censored) time (month) (month) 
Tumor size 
:;5 cm 58 (33) 54 6-102 0.0006 37 (17) 33 17-49 0.07 
>5 cm 39 (8) 14 9-19 35 (7) 14 8-20 
Tumor stage (TNM) 
I+II 33 (21) 95 2-188 0.001 22 (12) 42 26-58 0.06 
III 29 (11) 27 14-40 23 (7) 21 4-38 
IV 35 (9) 14 9-19 27 (5) 13 6-20 
Tumor multifocality 
solitary 43 (25) 95 5-185 0.001 31 (15) 33 21-45 0.007 
multiple 54 (16) 14 9-19 41 (9) 13 7-19 
Edmondson and Steiner's grade 
1 20 (13) 43 0.04 16 (10) 43 20-66 0.07 
2 44 (17) 27 12-42 31 (7) 15 5-25 
3+4 33 (11) 16 6-26 25 (7) 16 11-21 
MVI 
Absent 62 (31) 42 27-57 0.04 46 (18) 30 22-38 0.2 
Present 35 (10) 15 8-21 26 (6) 10 5-15 
HPIC 
Low 46 (25) 54 8-100 0.03 34 (15) 42 18-66 0.1 
High 51 (16) 16 13-19 38 (9) 15 11-18 
Surgical margins 
Negative 78 (37) 33 17-49 0.05 56 (22) 30 18-42 0.01 
Positive 14 (4) 9 7-11 11 (2) 9 6-12 
aFollowing factors did not show a significant impact on survival (p>0.2) and are omitted from this table for simplicity: concomitant liver 
cinhosis, etiology of underlying liver pathology (alcohol, hepatitis B, and hepatitis C), as well as preoperative AFP levels, cytolytic, and 
cholestatic parameters 
bTwo-sided p values obtained by log-rank test, which are considered to be significant if p<0.05, of marginal significance if 0.05'.Sp<O.l and 
NS if p?_O. l . 
cHPI was computed according to Lauwers et al. [23] 
Table 4 Details of some Cox regression models 
_.,,. 
N 
Ali patients( total 97, censored 41) Only patients treated by partial resection(total 72, censored 24) 
Modela Variables included Variables retained in p valuesb Relative 95% CI Variables retained p values Relative 95% CI 
the mode! risk c in the mode! riskc 
Stage, size, multifocality, Size >5 cm 0.009 2.1 1.2-3.5 Grade 0.05 
grade, HPid Multifocality=multiple 0.01 2.1 1.2-3.8 =grade 2 0.01 3.1 1.3-7.8 
=grade 3+4 0.07 2.3 0.9-5.9 
Multifocality 0.005 
=multiple 2.5 1.3-4.6 
2 Hep Par 1 =3 Hep Par 1 =3 0.01 2.le 1.2-3.6 CDlOcan 2:2 0.01 2.5r 1.2-4.8 
CDlOcan 2:2 CDlOcan 2:2 0.03 2.2e 1.1-4.3 CDIOcyt 2:1 0.03 2.lf 1.1-4.2 
CDIOcyt 2:1 CDIOcyt 2:1 0.02 2.2e 1.1-4.1 
3 Size, multifocality, Hep Par 1 =3 0.01 2.7 1.5-4.7 Multifocality=multiple 0.008 2.5 1.3-4.9 
grade, surgical margins, multifocality=multiple 0.04 2.4 1.3-4.4 Grade 0.06 
Hep Par 1 =3 =grade 2 0.02 3.0 1.2-7.5 
=grade 3+4 0.3 1.8 0.7-4.6 
Hep Par 1 =3 0.04 2.0 1.0-3.8 
4 Size, multifocality, Multifocality=multiple 0.001 2.8 1.5-5.0 Multifocality=multiple 0.006 2.5 1.3-4.9 
grade, surgical margins, CDIOcan 2:2 0.008 2.1 1.2-3.7 Grade 0.06 3.1 
CDlOcan 2:2 =grade 2 0.02 2.2 1.2-7.7 
=grade 3+4 0.1 0.9-5.7 
5 Size, multifocality, ers <4 0.001 3.5 1.7-7.3 ers <4 0.004 3.7 1.5-8.9 
grade, surgical margins, Multifocality=multiple 0.005 2.4 1.3-4.3 Multifocality=multiple 0.02 2.3 1.2-4.5 
crsg Grade 0.04 
=grade 2 0.01 3.2 1.3-8.2 
=grade 3+4 0.2 1.9 0.7-4.8 
6 Size, multifocality, ers <4 0.001 3.5 1.7-7.3 ers <4 0.004 3.7 1.5-8.9 
grade, cirrhosis, AFPh, Multifocality=multiple 0.005 2.4 1.3-4.3 Multifocality=multiple 0.02 2.3 1.2-4.5 
ers Grade 0.04 
=grade 2 0.01 3.2 1.3-8.2 
=grade 3+4 0.2 1.9 0.7-4.8 
aModel 1 includes only clinicopathological parameters. Mode! 2 includes only immunohistochemical parameters. Models 3 and 4 include clinicopathological parameters together with one 
immunohistochemical parameter. Models 5 and 6 include CIS in addition to clinicopathological parameters; both models retain the same final variables 
bSignificance of the Wald test, variables with p>0.05 were discarded from the mode! 
cFor dichotomous variables (size, multifocality and CIS), the relative risk is the predicted change of death hazard for a patient within the specified category as compared to the other one. For 
}.!'ade, the relative risk is such a change for a patient within the specified category as compared to the reference category (grade 1) 
HPI computed according to Lauwers et al. [23] 
ecorrelation coefficients for Hep Par 1 =3, CDlOcan 2:2, and CDlOcyt 2:1 are 0.721, 0.772, and 0.775, respectively 
rcorrelation coefficients for CDlOcan 2:2 and CDlOcyt 2:1 are 0.897 and 0.748, respectively 
gCIS (score Hep Par 1 staining + score CDlO canalicular staining - score CDlO cytoplasmic staining) 
hPreoperative AFP levels 
together with the selected clinicopathological parameters, 
Hep Par 1 and CD 1 Ocan were retained in the models 
(models 3 and 4 from Table 4, respectively). However, p 
values and relative risk were lower for Hep Par 1 and 
CDlOcan alone as compared to CIS (see below). 
All models testing CIS in conjunction with different 
clinicopathological parameters resulted in the retention of 
the same final variables. Models 5 and 6 from Table 4 are 
representative examples. CIS was the most significant prog-
nostic factor in both the complete cohort (p=0.001) and the 
subgroup ofliver-resected patients (p=0,004). Patients with 
a CIS <4, as compared to those with a CIS 2".4, had a 3.5-
fold (95% CI 1.7-7.3) and a 3.7-fold (95% CI 1.5-8.9) 
increased risk of death in the whole cohort and the sub-
group of patients with liver resection, respectively. In the 
model of the whole cohort, tumor multifocality was the 
only additional prognostic factor (p=0.005): patients with 
multifocal HCC had a 2.4-fold (95% CI 1.3 to 4.3) in-
creased risk of death as compared to those with solitaiy 
tumors. In the model of patients with liver resection only, 
tumor multifocality (p=0.02) and Edmondson and Steiner's 
grade (p=0.04) were retained in addition to CIS. 
Discussion 
Hepatocellular carcinoma is one of the most common 
malignant tumors worldwide that bas typically poor prog-
nosis regardless of the treatment, and its incidence and 
mortality are on the rise in Western nations [14]. Clinicians 
need prognostic indicators to inform their patients and to 
stratify them for eventual additional therapy. The present 
study of Hep Par 1 and CDlO expression in HCC by 
immunohistochemistry was undertaken to identify new 
prognostic markers for patients treated with curative intent 
by partial or total hepatectomy, the latter with liver 
transplantation. 
In our study population, strong cytoplasmic Hep Par 1 
and CD 1 Ocan expression, as well as absent CD lOcyt 
labeling, were correlated with longer overall survival. To 
obtain a practical algorithm for clinical use, these three 
immunohistochemical parameters were combined into a 
single immunohistochemical score, which showed a highly 
significant correlation with overall survival. Multivariate 
analysis proved CIS to be the most important independent 
prognostic factor, followed by tumor multifocality and 
Edmondson and Steiner's grade. Furthermore, CIS is su-
perior to Hep Par 1 or CD 10 scores alone with regard to 
risk assessment. To our knowledge, this is the first study to 
demonstrate the prognostic value ofthese markers, although 
their use is well documented in establishing the diagnosis 
of HCC [5, 7, 8, 38]. CIS was also the most significant 
prognostic indicator in the subgroup of patients treated by 
partial hepatectomy, which excludes the possibility of a bias 
due to the type of surgery. Unfortunately, the limited number 
of patients treated by total hepatectomy and the limited 
duration offollow-up precluded analysis ofthis subgroup. 
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A future study is planned to examine in detail the prog-
nostic value of Hep Par 1 and CD 10 in this group of patients. 
Prognostic indices are usually derived from the final Cox 
regression model by using the regression coefficients as 
weights for the corresponding scores [ 6]. However, we 
preferred a more simple prognostic index based on a weight 
of+ 1 for Hep Par 1 and CD 1 Ocan and a weight of -1 for 
CDlOcyt scores for two reasons. First, its determination is 
simple enough to be applicable in a routine setting. Second, 
as shown by the Cox model, including these three pa-
rameters, the absolu te value of their regression coefficients 
is roughly the same (about 0.7), whichjustifies a posteriori 
such a score. Interestingly, several parameters, such as 
TNM stage, tumor size, MVI, HPI, and surgical resection 
margins, which are known in the literature to be of prog-
nostic significance, were not retained in our Cox regression 
models. This can be explained by correlation of the im-
munohistochemical variables with these clinicopathologi-
cal parameters, as shown in Table 1 for tumor size and 
grade, MVI and HPI. Second, tumor multifocality, which 
remains significant in our multivariate models, contains 
paitly the same prognostic information as TNM stage, 
which is based on the former. 
The precise biological mechanisms underlying the im-
pact of Hep Par 1 and CD 10 expression on prognosis have 
yet to be identified. It might be linked to the fact that Hep 
Par 1 and CD 1 Ocan expressions are indicators of a high 
degree of differentiation. Indeed, in our series, there was a 
correlation between the expression of these markers and 
histological grade. These findings are in line with several 
reports in the literature [5, 8, 21, 39]. Another argument in 
favor ofthis hypothesis is the fact that poorly differentiated 
HCC are known to be devoid of bile canaliculi [5, 7]. 
Therefore, these tumors are frequently unreactive with 
antibodies directed against CD 10 which is a neutral endo-
peptidase located at the luminal aspects of bile canaliculi. 
To explain the intriguing feature of CD 1 Ocyt labeling in the 
less differentiated and more aggressive tumors, one might 
also speculate that redistribution of CD 10 from the cell 
surface to the cytoplasm is an indirect sign of lost cell 
polarity, which is one of the hallmarks of cancer [35]. This 
redistribution might be the consequence of aberrant gly-
cosylation, alternative splicing, or a truncating mutation of 
the CDlO gene [33, 36]. 
In conclusion, our study identifies Hep Par 1 and CD 10 
expression as the most informative predictors of overall 
survival in HCC patients treated by partial liver resection 
with curative intent. Introduction of these parameters in 
clinical decision making, however, requires confirmation 
ofthese preliminary findings in another population ofHCC 
patients. Whether these findings apply also to patients 
treated with total hepatectomy and liver transplantation as 
suggested by the present work will require further studies. 
Future prospective studies are also necessary to determine 
whether or not the CIS can be helpful for the choice of 
additional treatment and prediction ofprognosis in patients 
who are beyond curative surgery. 
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